Rationale, Design, and Implementation of Intensive Risk Factor Treatment in the CREST2 Trial.

ABSTRACT:

Background and purpose

The CREST2 trial (Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis) is comparing intensive medical management (IMM) alone to IMM plus revascularization with carotid endarterectomy or transfemoral carotid artery stenting for preventing stroke or death within 44 days after randomization or ipsilateral ischemic stroke thereafter. There are extensive clinical trial data on outcomes after revascularization of asymptomatic carotid stenosis, but not for IMM. As such, the experimental treatment in CREST2 is IMM, which is described in this article.

Methods

IMM consists of aspirin 325 mg/day and intensive risk factor management, primarily targeting systolic blood pressure <130 mm Hg (initially systolic blood pressure <140 mm Hg)

SUBMITTER: Turan TN 

PROVIDER: S-EPMC7530035 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature